Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MESAD: MSCs for Weaning From LVAD
NCT02460770Phase 1Withdrawn
- Sponsor
- Centre hospitalier universitaire de Toulouse
- Start
- Jun 2015
- Primary completion
- Jun 2017
- Countries
- 1
01
Overview
Phase 1, open-label trial of autologous mesenchymal stem cells in ischemic cardiomyopathy (ICM), sponsored by Centre hospitalier universitaire de Toulouse. Primary endpoint: Feasibility of the full procedure at 1 month. Planned start Jun 2015; status: withdrawn.
02
Drugs
autologous mesenchymal stem cells
03
Conditions
ischemic cardiomyopathy (ICM)
Beyond the preview
Go deeper on NCT02460770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02460770.